» Articles » PMID: 7813311

Comparative Acute Effects of Adenosine and Prostacyclin in Primary Pulmonary Hypertension

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 1995 Jan 1
PMID 7813311
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Vasodilators have been a main focus of therapy for primary pulmonary hypertension. Adenosine and prostacyclin have been shown to reduce pulmonary vascular resistance acutely in these patients. In order to compare the acute hemodynamic effects of adenosine and prostacyclin, ten patients with severe primary pulmonary hypertension, unresponsive to medical therapy, were studied. After baseline hemodynamics were obtained, an adenosine infusion, 50 to 100 ng/kg/min, was begun and titrated to the maximum tolerated dose. Hemodynamics were allowed to return to baseline, and thereafter, a prostacyclin infusion was begun at 2 ng/kg/min, and titrated to the maximum tolerated dose. Overall, adenosine (200 +/- 53 ng/kg/min) produced a 33 +/- 18% (p < 0.001) fall in pulmonary vascular resistance and a 52 +/- 25% (p < 0.001) increase in cardiac output with no effect on pulmonary or systemic arterial pressures. Prostacyclin (8 +/- 4 ng/kg/min) caused a 22 +/- 18% (p < 0.01) fall in pulmonary vascular resistance and a 25 +/- 26% (p < 0.05) increase in cardiac output with a 14 +/- 6% (p < 0.001) decrease in systemic arterial pressure, but no change in pulmonary arterial pressure. The effects of adenosine and prostacyclin on pulmonary vascular resistance were similar (r = 0.70, r2 = 0.49, p = 0.02). Adenosine and prostacyclin have similar hemodynamic effects acutely in primary pulmonary hypertension. Adenosine may be useful as a test of the potential for long-term prostacyclin therapy in patients with primary pulmonary hypertension.

Citing Articles

PeakPCO combined with FEV1/FVC predicts vasodilator-responsive patients with idiopathic pulmonary arterial hypertension.

Luo C, Qiu H, Wu C, He J, Yuan P, Zhao Q Pulm Circ. 2021; 11(4):20458940211059713.

PMID: 34881019 PMC: 8647237. DOI: 10.1177/20458940211059713.


Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights.

Ruffenach G, Hong J, Vaillancourt M, Medzikovic L, Eghbali M Respir Res. 2020; 21(1):303.

PMID: 33208169 PMC: 7677848. DOI: 10.1186/s12931-020-01570-2.


Vasodepressor Effects of Adenosine in the Cat are Independent of Cyclooxygenase, Potassium Channels, and Nitric Oxide Pathways.

Kaye A, Baber S, Sharief M, Kaye R, Cornett E Drugs R D. 2019; 19(4):319-328.

PMID: 31452117 PMC: 6890624. DOI: 10.1007/s40268-019-00283-2.


Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension.

Alencar A, Montes G, Barreiro E, Sudo R, Zapata-Sudo G Front Pharmacol. 2017; 8:858.

PMID: 29255415 PMC: 5722832. DOI: 10.3389/fphar.2017.00858.


Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis.

Langleben D, Orfanos S Pulm Circ. 2017; 7(3):588-597.

PMID: 28632001 PMC: 5841907. DOI: 10.1177/2045893217714231.